3,3′-Diindolylmethane enhances the efficacy of butyrate in colon cancer prevention through down-regulation of survivin

Cancer Prevention Research

Volumn 2, Issue 6, 2009, Pages 581-589

  Bhatnagar, Namrata ^a   Li, Xia ^a   Chen, Yue ^a   Zhou, Xudong ^b   Garrett, Scott H ^b   Guo, Bin ^a  

^a NORTH DAKOTA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,3 DIINDOLYLMETHANE; ANTINEOPLASTIC AGENT; BUTYRIC ACID; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; CYTOCHROME C; PROTEIN BAK; PROTEIN BAX; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SMALL INTERFERING RNA; SURVIVIN; UNCLASSIFIED DRUG; 3,3' DIINDOLYLMETHANE; 3,3'-DIINDOLYLMETHANE; BIRC5 PROTEIN, HUMAN; BUTYRIC ACID DERIVATIVE; COMPLEMENTARY DNA; HISTONE DEACETYLASE; HYBRID PROTEIN; INDOLE DERIVATIVE; MICROTUBULE ASSOCIATED PROTEIN; TUMOR PROTEIN;

ADENOMATOUS POLYPOSIS COLI GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER PREVENTION; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG POTENTIATION; GENE; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; ADENOCARCINOMA; ANIMAL; APOPTOSIS; BIOSYNTHESIS; COLON POLYPOSIS; COLON TUMOR; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE MUTANT; PATHOLOGY; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ADENOMATOUS POLYPOSIS COLI; ANIMALS; ANTICARCINOGENIC AGENTS; APOPTOSIS; BUTYRATES; CELL LINE, TUMOR; COLONIC NEOPLASMS; DNA, COMPLEMENTARY; DOWN-REGULATION; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, APC; HISTONE DEACETYLASES; HUMANS; INDOLES; MICE; MICE, MUTANT STRAINS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; RECOMBINANT FUSION PROTEINS;

EID: 68949170694     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0142     Document Type: Article

References (62)

1. Corpet DE, Pierre F. Point: From animalmodel s to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the modelsystem. Cancer Epidemiol Biomarkers Prev 2003;12:391-400.
2. Corpet DE, Pierre F. How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in rats, mice and men. Eur J Cancer 2005;41:1911-1922
3. Dashwood RH, Myzak MC, Ho E. Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention? Carcinogenesis 2006;27:344-349
4. Kuefer R, Hofer MD, Altug V, et al. Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. Br J Cancer 2004;90:535-541
5. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000;403:41-45
6. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001;1:194-202.
7. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 2003;4:13-18
8. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000;92:1210-1216
9. Hassig CA, Tong JK, Schreiber SL. Fiber-derived butyrate and the prevention of colon cancer. Chem Biol1997;4:783-789
10. Kim YS, Milner JA. Dietary modulation of colon cancer risk. J Nutr 2007;137:2576-9S.
11. Freeman HJ. Effects of differing concentrations of sodium butyrate on 1,2-dimethylhydrazine-induced rat intestinalneo plasia. Gastroenterology 1986;91:596-602.
12. Caderni G, Luceri C, Lancioni L, Tessitore L, Dolara P. Slow-release pellets of sodium butyrate increase apoptosis in the colon of rats treated with azoxymethane, without affecting aberrant crypt foci and colonic proliferation. Nutr Cancer 1998;30:175-181
13. Caderni G, Luceri C, De Filippo C, et al. Slow-release pellets of sodium butyrate do not modify azoxymethane (AOM)-induced intestinalc arcinogenesis in F344 rats. Carcinogenesis 2001;22:525-527
14. Huang X, Guo B. Adenomatous polyposis coli determines sensitivity to histone deacetylase inhibitor-induced apoptosis in colon cancer cells. Cancer Res 2006;66:9245-9251
15. Levy DB, Smith KJ, Beazer-Barclay Y, Hamilton SR, Vogelstein B, Kinzler KW. Inactivation of both APC alleles in human and mouse tumors. Cancer Res 1994;54:5953-5958
16. Kikuchi-Yanoshita R, Konishi M, Fukunari H, Tanaka K, Miyaki M. Loss of expression of the DCC gene during progression of colorectal carcinomas in familial adenomatous polyposis and nonfamilial adenomatous polyposis patients. Cancer Res 1992;52:3801-3803
17. Sidransky D, Tokino T, Hamilton SR, et al. Identification of ras oncogene mutations in the stoolof patients with curable colorectal tumors. Science 1992;256:102-105
18. Shirasawa S, Urabe K, Yanagawa Y, Toshitani K, Iwama T, Sasazuki T. p53 gene mutations in colorectal tumors from patients with familial polyposis coli. Cancer Res 1991;51:2874-2878
19. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003;1653:1-24.
20. Behrens J, von Kries JP, KuhlM, et al. Functional interaction of β-catenin with the transcription factor LEF-1. Nature 1996;382:638-642
21. Morin PJ. β-Catenin signaling and cancer. BioEssays 1999;21:1021-1030
22. Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 1990;247:322-324
23. Zhu P, Martin E, Mengwasser J, Schl ag P, Janssen KP, Gottlicher M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 2004;5:455-463
24. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003;3:46-54.
25. Wheatley SP, Carvalho A, Vagnarelli P, Earnshaw WC. INCENP is required for proper targeting of Survivin to the centromeres and the anaphase spindle during mitosis. Curr Biol2001;11:886-890
26. Aggarwal BB, Ichikawa H. Molecular targets and anticancer potentialof indole-3-carbinol and its derivatives. Cell Cycle 2005;4:1201-1215
27. Gong Y, Sohn H, Xue L, Firestone GL, Bjeldanes LF. 3,3′- Diindolylmethane is a novel mitochondrial H(+)-ATP synthase inhibitor that can induce p21 (Cip1/Waf1) expression by induction of oxidative stress in human breast cancer cells. Cancer Res 2006;66:4880-4887
28. Bhuiyan MM, Li Y, Banerjee S, et al. Down-regulation of androgen receptor by 3,3′-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells. Cancer Res 2006;66:10064-10072
29. Kong D, Banerjee S, Huang W, et al. Mammalian target of rapamycin repression by 3,3′-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D-overexpressing PC3 cells. Cancer Res 2008;68:1927-1934
30. Chen Y, Xu J, Jhala N, et al. Fas-mediated apoptosis in cholangiocarcinoma cells is enhanced by 3,3′-diindolylmethane through inhibition of AKT signaling and FLICE-like inhibitory protein. Am J Pathol2006;169:1833 -1842.
31. Kim EJ, Park SY, Shin HK, Kwon DY, Surh YJ, Park JH. Activation of caspase-8 contributes to 3,3′-diindolylmethane-induced apoptosis in colon cancer cells. J Nutr 2007;137:31-36
32. Rahman KM, Ali S, Aboukameel A, et al. Inactivation of NF-κB by 3,3′-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells. Mol Cancer Ther 2007;6:2757-2765
33. Rahman KW, Li Y, Wang Z, Sarkar SH, Sarkar FH. Gene expression profiling revealed survivin as a target of 3,3′-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells. Cancer Res 2006;66:4952-4960
34. Kong D, Li Y, Wang Z, Banerjee S, Sarkar FH. Inhibition of angiogenesis and invasion by 3,3′-diindolylmethane is mediated by the nuclear factor-κB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res 2007;67:3310-3319
35. Morin PJ, Vogelstein B, Kinzler KW. Apoptosis and APC in colorectal tumorigenesis. Proc Natl Acad Sci U S A 1996;93:7950-7954
36. Wolfensohn S, Lloyd M. Handbook of laboratory animalmanagement and welfare. Oxford: Blackwell; 1998.
37. O'Connor DS, Grossman D, Plescia J, et al. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci U S A 2000;97:13103-13107
38. Wall NR, O'Connor DS, Plescia J, Pommier Y, Altieri DC. Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res 2003;63:230-235
39. Lindsten T, Ross AJ, King A, et al. The combined functions of proapoptotic Bcl-2 family members bak and bax are essentialfor normaldevel opment of multiple tissues. Mol Cell 2000;6:1389-1399
40. Wei MC, Zong WX, Cheng EH, et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001;292:727-730
41. Chittenden T. BH3 domains: intracellular deathligands critical for initiating apoptosis. Cancer Cell 2002;2:165-166 (Pubitemid 41043968)
42. Gross A, JockelJ, Wei MC, Korsmeyer SJ. Enforced dimerization of BAX results in its translocation, mitochondriald ysfunction and apoptosis. Embo J 1998;17:3878-3885 (Pubitemid 28333974)
43. Guo B, Yin MB, Toth K, Cao S, Azrak RG, Rustum YM. Dimerization of mitochondrialBax is associated with increased drug response in Bax-transfected A253 cells. Oncol Res 1999;11:91-99
44. Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996;86:147-157 (Pubitemid 26256586)
45. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev 2001;15:2922-2933
46. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial-protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000;102:33-42.
47. Whitehead RH, Joseph JL. Derivation of conditionally immortalized cell lines containing the Min mutation from the normalcol onic mucosa and other tissues of an "Immortomouse"/Min hybrid. Epithelial Cell Biol 1994;3:119-125
48. Topping DL, Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol Rev 2001;81:1031-1064
49. Roediger WE. Utilization of nutrients by isolated epithelial cells of the rat colon. Gastroenterology 1982;83:424-429 (Pubitemid 12078229)
50. Hague A, Manning AM, Hanlon KA, Huschtscha LI, Hart D, Paraskeva C. Sodium butyrate induces apoptosis in human colonic tumour cell lines in a p53-independent pathway: implications for the possible role of dietary fibre in the prevention of large-bowel cancer. Int J Cancer 1993;55:498-505. (Pubitemid 23300605)
51. Heerdt BG, Houston MA, Augenlicht LH. Potentiation by specific short-chain fatty acids of differentiation and apoptosis in human colonic carcinoma cell lines. Cancer Res 1994;54:3288-3293
52. Heerdt BG, Houston MA, Augenlicht LH. Shortchain fatty acid-initiated cell cycle arrest and apoptosis of colonic epithelial cells is linked to mitochondrial-function. Cell Growth Differ 1997;8:523-532
53. Wong JM, de Souza R, Kendall CW, Emam A, Jenkins DJ. Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol 2006;40:235-243 (Pubitemid 44309560)
54. Lupton JR. Microbialdegradation products influence colon cancer risk: the butyrate controversy. J Nutr 2004;134:479-482
55. Zoran DL, Turner ND, Taddeo SS, Chapkin RS, Lupton JR. Wheat bran diet reduces tumor incidence in a rat modelof colon cancer independent of effects on distall uminal butyrate concentrations. J Nutr 1997;127:2217-2225
56. Jung M. Inhibitors of histone deacetylase as new anticancer agents. Curr Med Chem 2001;8:1505-1511 (Pubitemid 32894012)
57. Ambrosini G, Adida C, Sirugo G, Altieri DC. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J BiolChem 1998;273:11177-11182 (Pubitemid 28204967)
58. Kanwar JR, Shen WP, Kanwar RK, Berg RW, Krissansen GW. Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst 2001;93:1541-1552
59. Pennati M, Binda M, De Cesare M, et al. Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo. Carcinogenesis 2004;25:1129-1136 (Pubitemid 38968040)
60. Mesri M, Wall NR, Li J, Kim RW, Altieri DC. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest 2001;108:981-990 (Pubitemid 32946072)
61. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008;8:61-70.
62. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004;116:205-219 (Pubitemid 38167313)